Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
about
Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritisValdecoxib for the management of chronic and acute pain.Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor.Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Valdecoxib : the rise and fall of a COX-2 inhibitor.Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.A pragmatic observational feasibility study on integrated treatment for musculoskeletal disorders: Design and protocol.Utility and sensitivity of the sore throat pain model: results of a randomized controlled trial on the COX-2 selective inhibitor valdecoxib.Valdecoxib provides effective pain relief following acute ankle sprain.Value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis.Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects.A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.How celecoxib could be safer, how valdecoxib might have been.Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity.The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial.Empirical performance of the case-control method: lessons for developing a risk identification and analysis system.Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity
P2860
Q28218359-CDE4119A-9A52-4CF3-A618-964372C92A3CQ34557067-74B546D8-B26D-4019-8C28-60893D99B2E3Q35043366-37E32EDB-4888-4DC7-97B7-5EA00F914A01Q35080062-D709E0B8-798B-4BB9-9890-76C92140AA51Q35873867-61BFBD1C-BDF5-4454-9408-DF835EEBE3ADQ35875744-DDBC1B36-860F-4D5B-A92A-813EF548EBD2Q36013803-F80389F6-222A-410F-8408-B64F30DE5203Q36486905-088B45D4-0F07-48C0-98C1-4EA0E2527A26Q37893966-FAB003AE-8E4A-4093-932A-707308EB8304Q38091707-88D9405C-4117-431A-96E6-6C62DDFB5E42Q38962092-2A131766-1071-493E-AFA3-0A256B95D94EQ38993297-B5FDE42E-F399-48F2-AECD-8D7D9ED3D45AQ39294875-E592AD7A-EE06-416D-A0FE-BE108FDF2047Q39334964-60AC95C9-B74C-4F98-92E0-72DF59EBD69AQ39342991-214E6E77-71F2-47AA-AD10-CD0D9FF88DF3Q40492471-2E1FF5B4-F02C-4290-AF1A-E6C7E034F2F9Q44346618-C57DE3AC-4187-4DA0-8883-0DBE780E24C6Q44505180-AD11D855-E8B9-4AA2-8B64-C270ADB184C1Q44700975-8731752F-4EA9-417A-8A08-25C3C2EE62F6Q46138266-58DDC376-3AA0-4C27-A7B5-CED9B1F1F4BBQ46447275-4D2E0E72-ABAE-4067-AD8F-FBF5B9495F9FQ46669656-27D3CDEB-48C6-460C-9FCF-6C7D67C8FF35Q46943251-6089BC5C-19D1-404B-B261-0EAC364EFD7BQ48405366-4A3FCEF5-720F-4364-AEFD-C2D30F23183CQ57169425-BDD5EABE-EBFC-4F22-860A-045198708767
P2860
Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy and safety of the COX ...... lled comparison with naproxen.
@ast
Efficacy and safety of the COX ...... lled comparison with naproxen.
@en
Efficacy and safety of the COX ...... lled comparison with naproxen.
@nl
type
label
Efficacy and safety of the COX ...... lled comparison with naproxen.
@ast
Efficacy and safety of the COX ...... lled comparison with naproxen.
@en
Efficacy and safety of the COX ...... lled comparison with naproxen.
@nl
prefLabel
Efficacy and safety of the COX ...... lled comparison with naproxen.
@ast
Efficacy and safety of the COX ...... lled comparison with naproxen.
@en
Efficacy and safety of the COX ...... lled comparison with naproxen.
@nl
P2093
P356
P1476
Efficacy and safety of the COX ...... lled comparison with naproxen.
@en
P2093
David P Recker
Terry Bevirt
W Makarowski
William W Zhao
P304
P356
10.1053/JOCA.2001.0510
P577
2002-04-01T00:00:00Z